Dry-powder inhalers in acute asthma

Area of Science:

• Pulmonology
• Pharmacology
• Respiratory Medicine

Background:

• Acute asthma exacerbations require prompt and effective bronchodilator therapy.
• Different inhaler devices exist for delivering medications, including dry powder inhalers (DPIs), pressurized metered-dose inhalers (pMDIs), and nebulizers.
• The efficacy of rapid-acting beta2-agonists via DPIs in acute asthma settings warrants evaluation.

Purpose of the Study:

• To evaluate the efficacy of rapid-acting beta2-agonists delivered via DPIs for treating moderate-to-severe acute asthma.
• To compare the effectiveness of DPIs with pMDIs and nebulizers in acute asthma management.

Main Methods:

• An updated literature search was conducted covering studies from 1985 to December 2012.
• Included were 23 randomized, double-blind, or open clinical studies in acute asthma.
• Studies compared DPIs with pMDIs (with or without spacers) or nebulizers under controlled hospital conditions.

Main Results:

• Administration of beta2-agonist bronchodilators (formoterol, salbutamol, terbutaline, budesonide/formoterol) via DPIs was found to be effective during severe asthma worsening and acute attacks.
• DPIs demonstrated equivalent efficacy to established therapies using pMDIs or nebulization.
• Patients can confidently use DPIs as an alternative to other inhaler devices during asthma exacerbations.

Conclusions:

• Dry powder inhalers are an effective and reliable option for delivering rapid-acting beta2-agonists in the management of moderate-to-severe acute asthma.
• The findings support the use of DPIs as a viable alternative to pMDIs and nebulizers for patients experiencing asthma worsening.
• This review provides evidence for the equivalent efficacy of DPIs, ensuring patient trust in these devices during acute asthma episodes.